

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

**Danter et al.**

Serial No.:

**10/531,107**

Filed:

**November 7, 2005**

For:

**Protein Tyrosine Kinase Inhibitors**

Group Art Unit:

**1624**

Examiner:

**Rao, Deepak R.**

Confirmation Number:

**2708**

Docket No.: **221904-1030**

**AMENDMENT AFTER ALLOWANCE PURSUANT TO 37 CFR 1.312**

Mail Stop – Issue Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

The Notice of Allowance mailed July 29, 2009, has been received with thanks. Upon review of the specification and claims, Applicants noted some cosmetic changes, which are embodied in the amendments to the specification below. Pursuant to 37 C.F.R. 1.312, please enter the following amendments. Applicants respectfully submit that the amendments herein merely embody the correction of formal matters and do not alter the scope or substance of the application.

It is not believed that extensions of time or fees for net addition of claims are required, beyond those that may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to deposit account no. 20-0778.